Microfluidic systems in cancer research

Caballero, David; Luque-González, Maria Angélica; Reis, Rui L.; Kundu, Subhas C.

doi:10.1016/b978-0-12-818128-7.00015-0

Cited by 8 publications

(1 citation statement)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the field of cancer, microfluidic platforms offer the prospect to recapitulate the tumor and disease microenvironment and advance our understanding of disease pathophysiology by modeling disease processes, e.g., intravasation, extravasation, angiogenesis, invasiveness, migration, and adhesion [278,288]. Microfluidic devices have also been used as diagnostic tools for biomarker analysis and assessment of cell sensitivity to drugs in a patient personalized manner [289], by employing devices customized with patient's own cells [290]. This technology is advantageous compared to other in vitro models because it is possible to replicate physiological properties more accurately, e.g., hydrodynamic forces, shear forces and nutrient gradients, by setting the appropriate load volumes and flow rate.…”

Section: On-chip Models Of Acute Myeloid Leukemiamentioning

confidence: 99%

Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern

Dozzo

Galvin

Shin

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous malignancy affecting myeloid cells in the bone marrow (BM) but can spread giving rise to impaired hematopoiesis. AML incidence increases with age and is associated with poor prognostic outcomes. There has been a disconnect between the success of novel drug compounds observed in preclinical studies of hematological malignancy and less than exceptional therapeutic responses in clinical trials. This review aims to provide a state-of-the-art overview on the different preclinical models of AML available to expand insights into disease pathology and as preclinical screening tools. Deciphering the complex physiological and pathological processes and developing predictive preclinical models are key to understanding disease progression and fundamental in the development and testing of new effective drug treatments. Standard scaffold-free suspension models fail to recapitulate the complex environment where AML occurs. To this end, we review advances in scaffold/matrix-based 3D models and outline the most recent advances in on-chip technology. We also provide an overview of clinically relevant animal models and review the expanding use of patient-derived samples, which offer the prospect to create more “patient specific” screening tools either in the guise of 3D matrix models, microphysiological “organ-on-chip” tools or xenograft models and discuss representative examples. Graphical abstract

show abstract

Section: On-chip Models Of Acute Myeloid Leukemiamentioning

confidence: 99%

Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern

Dozzo

Galvin

Shin

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

Cancer Traps: Implantable and On‐Chip Solutions for Early Cancer Detection and Treatment

Caballero

Reis

Kundu

2023

Adv Materials Technologies

Self Cite

View full text Add to dashboard Cite

Cancer continues to be a major global health issue causing millions of deaths annually. While traditional therapeutic methods may be effective in many cases, they may not be suitable for highly metastatic cancers. Moreover, the late detection of tumors, when they have already spread and are harder to treat, further exacerbates the challenge in managing this disease. As a result, there is a growing interest in developing complementary tissue‐engineered approaches for early cancer diagnosis and treatment to enhance patient recovery. Bioengineered cancer traps have gained significant attention due to their efficacy and ease of use. These trapping systems employ (bio)chemical and mechanical strategies to selectively capture and limit the spread of cancer cells, leading to their eradication from the body. Furthermore, when integrated into microfluidic devices, these cancer traps‐on‐a‐chip can be used for liquid biopsy and the early detection of circulating tumor cells and other tumor‐derived material, allowing for precision medicine treatments. Herein, this innovative approach to cancer theranostics, including its mechanism of action, current stage of development, and potential advantages and limitations is discussed.

show abstract

Emerging Microfluidic and Biosensor Technologies for Improved Cancer Theranostics

Caballero

Abreu

Reis

et al. 2022

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Microfluidic systems in cancer research

Cited by 8 publications

References 167 publications

Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern

Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern

Cancer Traps: Implantable and On‐Chip Solutions for Early Cancer Detection and Treatment

Emerging Microfluidic and Biosensor Technologies for Improved Cancer Theranostics

Contact Info

Product

Resources

About